FGAM
ALNY icon

Financial Gravity Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Financial Gravity Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1
Closed -$213 – 1423
2024
Q1 		$213 Buy
+1
New +$167 ﹤0.01% 933

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Financial Gravity Asset Management's ALNY Position: Q2 2024 in Review

Financial Gravity Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2024, closing a stake of 1 share — an estimated $213 sold.

Financial Gravity Asset Management first reported a position in ALNY in Q1 2024 and held it in 1 quarter. The position peaked at $213 in Q1 2024. 523 funds tracked by Wall St. Rank hold ALNY as of Q2 2024.

  • Financial Gravity Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Financial Gravity Asset Management sold 1 Alnylam Pharmaceuticals share in Q2 2024, an estimated $213.
  • Financial Gravity Asset Management first reported a position in Alnylam Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Financial Gravity Asset Management's Alnylam Pharmaceuticals position peaked at $213 in Q1 2024.
  • 523 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2024.

Based on Financial Gravity Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.